BR112017018834A2 - variantes de protoxina-ii e métodos de uso - Google Patents

variantes de protoxina-ii e métodos de uso

Info

Publication number
BR112017018834A2
BR112017018834A2 BR112017018834A BR112017018834A BR112017018834A2 BR 112017018834 A2 BR112017018834 A2 BR 112017018834A2 BR 112017018834 A BR112017018834 A BR 112017018834A BR 112017018834 A BR112017018834 A BR 112017018834A BR 112017018834 A2 BR112017018834 A2 BR 112017018834A2
Authority
BR
Brazil
Prior art keywords
protoxin
variants
methods
preparing
relates
Prior art date
Application number
BR112017018834A
Other languages
English (en)
Inventor
Wickenden Alan
Flinspach Mack
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112017018834A2 publication Critical patent/BR112017018834A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

a presente invenção refere-se a variantes de protoxina-ii, polinucleotídeos que codificam as mesmas e métodos de preparo e uso dos mesmos.
BR112017018834A 2015-03-03 2016-02-25 variantes de protoxina-ii e métodos de uso BR112017018834A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127339P 2015-03-03 2015-03-03
PCT/US2016/019549 WO2016140859A2 (en) 2015-03-03 2016-02-25 Protoxin-ii variants and methods of use

Publications (1)

Publication Number Publication Date
BR112017018834A2 true BR112017018834A2 (pt) 2018-04-17

Family

ID=56849056

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018834A BR112017018834A2 (pt) 2015-03-03 2016-02-25 variantes de protoxina-ii e métodos de uso

Country Status (15)

Country Link
US (3) US20160257726A1 (pt)
EP (1) EP3265476A4 (pt)
JP (2) JP2018512123A (pt)
KR (1) KR20170120703A (pt)
CN (1) CN107531769A (pt)
AR (1) AR103838A1 (pt)
AU (2) AU2016226443B2 (pt)
BR (1) BR112017018834A2 (pt)
CA (1) CA2978435A1 (pt)
HK (1) HK1249118A1 (pt)
IL (2) IL254273A0 (pt)
MA (1) MA41642A (pt)
MX (1) MX2017011223A (pt)
TW (1) TW201706292A (pt)
WO (1) WO2016140859A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
WO2015051216A1 (en) 2013-10-03 2015-04-09 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
KR20170097020A (ko) 2014-12-23 2017-08-25 오토메드 피티와이 리미티드 딜리버리 장치, 시스템 및 관련 방법
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
EP3277304B1 (en) * 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
CN109369784B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 PaTx-1毒素及其应用
CN109369785B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 Ccotx1毒素及其应用
CN114957431B (zh) * 2022-06-27 2023-06-20 四川丽妍工坊生物科技有限公司 一种皮肤抗皱多肽Cj2a2、制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
RU2218407C2 (ru) 1997-04-16 2003-12-10 Юниджен Лэбораториз Инк. Прямая экспрессия пептидов в культуральные среды
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
EP1538206B1 (en) 1997-09-16 2010-03-24 Centocor, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
EP2081602A2 (en) 2006-10-25 2009-07-29 Amgen Inc. Toxin peptide therapeutic agents
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
WO2010104115A1 (ja) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
JP5555891B2 (ja) 2009-09-15 2014-07-23 アロモネ プリクリニカル リミテッド クモ毒から単離した新規ペプチド及びその使用
US9279003B2 (en) * 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
JP2014507136A (ja) 2011-01-18 2014-03-27 アムジエン・インコーポレーテツド ＮａＶ１．７ノックアウトマウスとそれらの使用
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9102751B2 (en) * 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
WO2013173706A2 (en) 2012-05-18 2013-11-21 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
WO2014016673A1 (en) 2012-07-27 2014-01-30 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
WO2015051216A1 (en) * 2013-10-03 2015-04-09 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
EP3277304B1 (en) 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use

Also Published As

Publication number Publication date
WO2016140859A2 (en) 2016-09-09
IL282482A (en) 2021-06-30
AR103838A1 (es) 2017-06-07
EP3265476A2 (en) 2018-01-10
HK1249118A1 (zh) 2018-10-26
US10995125B2 (en) 2021-05-04
JP2018512123A (ja) 2018-05-17
KR20170120703A (ko) 2017-10-31
CN107531769A (zh) 2018-01-02
JP2022071050A (ja) 2022-05-13
US20170334959A1 (en) 2017-11-23
AU2021200400A1 (en) 2021-03-18
US20210363204A1 (en) 2021-11-25
AU2016226443A1 (en) 2017-09-21
EP3265476A4 (en) 2018-08-22
TW201706292A (zh) 2017-02-16
MX2017011223A (es) 2018-06-20
WO2016140859A3 (en) 2016-10-27
MA41642A (fr) 2018-01-09
US20160257726A1 (en) 2016-09-08
CA2978435A1 (en) 2016-09-09
IL254273A0 (en) 2017-10-31
AU2016226443B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
BR112018073384A2 (pt) polinucleotídeos moduladores
CO2018005614A2 (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
BR112018007017A2 (pt) polipeptídeos
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
IL253072A0 (en) Adding commands in software code for self-defense of an application while running
CL2016002455A1 (es) Anticuerpos multiespecíficos.
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
NI201400125A (es) Antagonistas de st2l y métodos de uso
DK3090696T3 (da) Fjederbelastet ballon
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018011504A2 (pt) microcápsulas de trombina
BR112017002662A2 (pt) processo para preparar furfural e/ou derivados de furfural.
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
UY36187A (es) Anticuerpos antagonistas de interferón alfa y omega

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2763 DE 19/12/2023.